Wednesday, January 24, 2018 12:02:10 AM
BB -
I am jomama's friend. There was an issue with my account and I haven't been able to post for the longest time. I follow the message board closely and am long AMRN. I appreciate your daily posts.
The brief is currently under seal for one of two reasons: (1) AMRN filed it under seal, or (2) court order. Let's take the latter first. If the brief is filed under seal due to a court order, it is either in the form of a stipulation between the parties (I do not see one on the docket), or a protective order has been entered (this could be an issue of contention). I do not see a protective order entered on the docket or moving papers to support the entry of a protective order. Thus, in my experience, unless there are some extraordinary circumstances at work, AMRN filed the brief under seal.
Most telling: the brief was filed very late in the evening. There are no court employees who "screen" the content or substance of filings. The filing party literally chooses to file a document under seal or not. Although I have never filed in the Federal Circuit Court of Appeals, I file in its sister court, the Third Circuit Court of Appeals (highest circuit court in my jurisdiction). Given my practice, I've filed several briefs under seal and we typically file things later in the evening on filing deadlines for strategic reasons.
You cite to FRCP 5.2(e). The rule states that the court may, for good cause, limit non-party access to filings. I've seen this occur once in my career, and it was not until one of the parties moved for an "emergency" protective order. That is not to say that the Court cannot, sua sponte, enter an order limiting access to non-parties, but I believe that would constitute extraordinary circumstances. In this case, given the timing of the filing, I find it extremely unlikely that the court reviewed the filing and decided to restrict access. As an aside, your guess is as good as mine as to what constitutes the nebulous "good cause" standard.
Also, take a look at local rule 25(f), governing privacy: "[t]he responsibility for redacting restricted or sensitive materials from documents and assuring that all materials contained in the public version of documents rests solely with the parties and counsel. The clerk of court will not review documents filed for compliance with this requirement."
In sum, I believe AMRN filed the brief under seal to protect proprietary information contained therein. When we consider the core arguments that AMRN would have raised in the ITC, which is intrinsically one of the factors for consideration on appeal, I find it more than likely that AMRN "let it fly" in its brief. In other words, in order to establish that the ITC acted arbitrarily in declining to investigate, AMRN likely got into the merits of exactly how DS are misleading the public re EPA, and that requires a discussion of both public and private (proprietary) information.
Hope this helps. I completely agree with you that given AMRN's volume today, this certainly affected the PPS.
I am jomama's friend. There was an issue with my account and I haven't been able to post for the longest time. I follow the message board closely and am long AMRN. I appreciate your daily posts.
The brief is currently under seal for one of two reasons: (1) AMRN filed it under seal, or (2) court order. Let's take the latter first. If the brief is filed under seal due to a court order, it is either in the form of a stipulation between the parties (I do not see one on the docket), or a protective order has been entered (this could be an issue of contention). I do not see a protective order entered on the docket or moving papers to support the entry of a protective order. Thus, in my experience, unless there are some extraordinary circumstances at work, AMRN filed the brief under seal.
Most telling: the brief was filed very late in the evening. There are no court employees who "screen" the content or substance of filings. The filing party literally chooses to file a document under seal or not. Although I have never filed in the Federal Circuit Court of Appeals, I file in its sister court, the Third Circuit Court of Appeals (highest circuit court in my jurisdiction). Given my practice, I've filed several briefs under seal and we typically file things later in the evening on filing deadlines for strategic reasons.
You cite to FRCP 5.2(e). The rule states that the court may, for good cause, limit non-party access to filings. I've seen this occur once in my career, and it was not until one of the parties moved for an "emergency" protective order. That is not to say that the Court cannot, sua sponte, enter an order limiting access to non-parties, but I believe that would constitute extraordinary circumstances. In this case, given the timing of the filing, I find it extremely unlikely that the court reviewed the filing and decided to restrict access. As an aside, your guess is as good as mine as to what constitutes the nebulous "good cause" standard.
Also, take a look at local rule 25(f), governing privacy: "[t]he responsibility for redacting restricted or sensitive materials from documents and assuring that all materials contained in the public version of documents rests solely with the parties and counsel. The clerk of court will not review documents filed for compliance with this requirement."
In sum, I believe AMRN filed the brief under seal to protect proprietary information contained therein. When we consider the core arguments that AMRN would have raised in the ITC, which is intrinsically one of the factors for consideration on appeal, I find it more than likely that AMRN "let it fly" in its brief. In other words, in order to establish that the ITC acted arbitrarily in declining to investigate, AMRN likely got into the merits of exactly how DS are misleading the public re EPA, and that requires a discussion of both public and private (proprietary) information.
Hope this helps. I completely agree with you that given AMRN's volume today, this certainly affected the PPS.
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
